CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline.
about
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug responsePharmacogenetics of schizophrenia.The influence of ethnicity and antidepressant pharmacogenetics in the treatment of depression.Tolerability and safety of fluvoxamine and other antidepressants.The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifeneSelective serotonin reuptake inhibitors: a review of its effects on intraocular pressurePsychopharmacogenetics--a challenge for pharmacotherapy in psychiatry.Pathophysiology of depression and mechanisms of treatmentPharmacogenetics of cytochrome p4502D6: genetic background and clinical implication.The burden and management of cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interaction (DDI): co-medication of metoprolol and paroxetine or fluoxetine in the elderly.Antidepressant-drug interactions are potentially but rarely clinically significant.Inhibition of Efavirenz Metabolism by Sertraline and Nortriptyline and Their Effect on Efavirenz Plasma Concentrations.Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice.The role of cytochrome P450 in antiretroviral drug interactions.Repeated administration of berberine inhibits cytochromes P450 in humansFetal serotonin reuptake inhibitor antidepressant exposure: maternal and fetal factors.Challenges in pharmacogenetics.Treatment of depression with selective serotonin inhibitors: the role of fluvoxamine.CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers.Safe and effective medicines for all: is personalized medicine the answer?Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression.Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers.Discontinuation and dose adjustment of metoprolol after metoprolol-paroxetine/fluoxetine co-prescription in Dutch elderly.CYP450 genotype and pharmacogenetic association studies: a critical appraisal
P2860
Q28252209-A57A84CA-D8C7-49E8-A385-4E716831CF70Q33920521-468363A8-6A92-4AD8-8352-EC84F30B2958Q33924148-5E9F2BE7-6B7C-443D-91F3-1404B3ABA07AQ33995120-682C5CD7-D892-437F-997E-17FE51F3DE01Q34537662-3BEACEDC-42F9-4725-9359-F863E3CCB5F6Q34568883-7D3A36B7-DE20-4820-B54C-F30AE4A7E677Q34658800-07D211A1-D0B2-4CFF-B7C2-233F0775167DQ35066468-D767F2CE-3A89-48E1-888B-27861A096D4DQ35236438-AC82E331-7007-44D7-BD2F-75EE3D0A5CE0Q35594563-BD15C8A2-C2A2-4923-B593-5CD7CC62CC07Q36323469-8E87F879-6F0F-4336-86BA-B5F5628AF37DQ36538987-B8E3A6B3-DE3E-436C-9BBA-300A6AACF363Q36571936-35065638-BCB5-4FF0-9A6A-B8B72288C89AQ36702588-27E17545-CAE0-47FC-81B3-F492D14BA6B6Q36909336-5C175EA3-4C06-4455-9C95-4728B452CE4EQ36983633-A677CD38-21D6-4516-92DD-515A36D3481BQ38052726-11D37D03-34B2-4EE9-BD5D-E16AC69978E3Q38103767-0FBA9EAA-FDC3-4D06-AAF0-68E223CCED59Q38221223-A2655727-F966-4C11-8005-657A4B6168C4Q44098828-FCE8DA62-CBA1-4023-BA8C-16F072096D01Q44202468-031EC2E6-A06B-42AF-ABE2-722A3E0B150FQ44483899-7E5AF056-A203-4957-B9EE-E87E7629A66FQ44852169-989AB3E7-56E2-473B-B779-2FFF8D61CD4AQ53619639-B4BE3AAF-FE68-413A-8D27-725BE4FC9B92Q55396723-90F03860-DA1F-4E82-B4CE-3AE5606DA692Q57585515-85A1861F-002D-4B58-8453-7A16720591B9
P2860
CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline.
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
CYP2D6 status of extensive met ...... ne, paroxetine, or sertraline.
@ast
CYP2D6 status of extensive met ...... ne, paroxetine, or sertraline.
@en
type
label
CYP2D6 status of extensive met ...... ne, paroxetine, or sertraline.
@ast
CYP2D6 status of extensive met ...... ne, paroxetine, or sertraline.
@en
prefLabel
CYP2D6 status of extensive met ...... ne, paroxetine, or sertraline.
@ast
CYP2D6 status of extensive met ...... ne, paroxetine, or sertraline.
@en
P2093
P1476
CYP2D6 status of extensive met ...... ne, paroxetine, or sertraline.
@en
P2093
P304
P356
10.1097/00004714-199904000-00011
P407
P577
1999-04-01T00:00:00Z